相关实验视频

Updated: Jul 5, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

在细胞癌中免疫治疗的既定和新兴生物标志物

Yash Jani¹, Caroline S Jansen^2,3, Margo B Gerke²

¹Mercer University, Macon, GA 31207, USA.

|January 24, 2024

概括

生物标志物对于预测细胞癌 (RCC) 患者对免疫治疗的反应至关重要. 这有助于最大限度地提高治疗效益,并最大限度地减少不良事件,以改善患者的治疗结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

免疫疗法,包括免疫检查点抑制剂,在细胞癌 (RCC) 治疗中表现有前途.
然而,患者反应和副作用的变化需要预测生物标志物.

研究的目的:

审查目前和新兴的RCC免疫疗法生物标志物.
引导选择可能从免疫疗法中受益的患者,并确定那些有不良事件风险的患者.

主要方法:

关于RCC免疫疗法生物标志物的当前实践和新兴创新的文献综述.

主要成果:

讨论生物标志物在优化RCC患者免疫治疗选择中的作用.
强调需要临床生物标志物来提高患者的安全性和治疗疗效.

结论:

生物标志物开发对于RCC个性化免疫疗法至关重要.
改善治疗反应和不良事件的预测将提高患者的治疗结果.

关键词:

癌症免疫学癌症免疫学检查点抑制剂检查点抑制剂临床免疫学临床免疫学免疫学标志物免疫学标志物免疫疗法免疫疗法

更多相关视频

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.